Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Código da empresaILMN
Nome da EmpresaIllumina Inc
Data de listagemJun 28, 2000
Fundado em2000
CEOMr. Jacob Thaysen, Ph.D.
Número de funcionários8970
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 28
Endereço5200 Illumina Way
CidadeSAN DIEGO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal92122
Telefone18582024500
Sitehttps://www.illumina.com
Código da empresaILMN
Data de listagemJun 28, 2000
Fundado em2000
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados